Associated Papers
Luteolin protects DYT-PRKRA cells from apoptosis by suppressing PKR activation.
Frederick K et al.
Frontiers in Pharmacology, 2023
DYT-PRKRA Mutation P222L Enhances PACT's Stimulatory Activity on Type I Interferon Induction.
Vaughn LS et al.
Biomolecules, 2022
Dystonia 16 (DYT16) mutations in PACT cause dysregulated PKR activation and eIF2α signaling leading to a compromised stress response.
Burnett SB et al.
Neurobiology of Disease, 2020
A truncated PACT protein resulting from a frameshift mutation reported in movement disorder DYT16 triggers caspase activation and apoptosis.
Burnett SB et al.
Journal of Cellular Biochemistry, 2019
Altered activation of protein kinase PKR and enhanced apoptosis in dystonia cells carrying a mutation in PKR activator protein PACT.
Vaughn LS et al.
The Journal of Biological Chemistry, 2015
Novel compound heterozygous mutations in PRKRA cause pure dystonia.
de Carvalho Aguiar P et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2015
Reply to letter: Novel compound heterozygous mutations in PRKRA cause pure dystonia.
Zech M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2015
A novel presentation of DYT 16: acute onset in infancy and association with MRI abnormalities.
Lemmon ME et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2013
Select a paper to view details